Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 07, 2015 1:23 AM ET


Company Overview of MyoKardia, Inc.

Company Overview

MyoKardia, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is MYK-461, a small molecule that is in three Phase I clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy (HCM). The company also develops DCM-1, a product candidate that treats heritable dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart. In addition, it develops HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients; and LUS-1...

333 Allerton Avenue

South San Francisco, CA 94080

United States

Founded in 2012

51 Employees



Key Executives for MyoKardia, Inc.

Chief Executive Officer, President and Director
Age: 42
Age: 73
Compensation as of Fiscal Year 2015.

MyoKardia, Inc. Key Developments

MyoKardia Seeks Acquisitions

MyoKardia, Inc. is seeking acquisitions. MyoKardia intends to use the net proceeds from IPO to in-license, acquire or invest in new businesses, technology or assets.

MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy

MyoKardia, Inc. announced it has initiated dosing in a Phase 1 clinical trial of MYK-461. MYK-461 is the first ever therapy designed to target the underlying cause of hypertrophic cardiomyopathy (HCM), the most common heritable cardiovascular disease. Patients with HCM are born with a mutation that causes over-contraction of the heart muscle cells, leading to thickening and stiffening of the heart muscle. Patients with HCM live with often debilitating disease symptoms including shortness of breath, chest pain and fainting spells. Complications of HCM include progressive heart failure, abnormal heart rhythms, stroke and sudden cardiac death. MyoKardia is developing a portfolio of potential treatments for HCM, each of which is designed to specifically target one of the underlying molecular mechanisms causing the disease. MYK-461 is the first potential treatment in MyoKardiaâ s HCM portfolio to enter clinical development. MYK-461 has been designed to correct one of the most common molecular mechanisms causing HCM, and the clinical program will evaluate patients whose disease is caused by this specific mechanism, as identified by genetic screening. In conjunction with the initiation of MYK-461â s Phase 1 study, the company also announced the expansion of its management team with the appointment of Ingrid Boyes to senior vice president, human resources and Steven Chan to vice president, corporate controller.

MyoKardia, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015

MyoKardia, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015 . Venue: JW Marriott Essex House, 160 Central Park South, b/w 6th & 7th Avenue, New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
Roex Inc. United States
Blessed Herbs, Inc. United States
Schering Berlin, Inc. United States
Atterx BioTherapeutics, Inc. United States
AgroLabs, Inc. United States

Recent Private Companies Transactions

Private Placement
April 20, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MyoKardia, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at